Reassortant BTV and AHSV vaccines
AssigneesThe University Court of the University of Glasgow, Boehringer Ingelheim Animal Health USA Inc.
InventorsMassimo Palmarini, Sandro Filipe Nunes, Pascal Hudelet, Jean Christophe Audonnet
Life of this patent
Estimating the term…
Abstract
The present invention encompasses BTV and ASHV vaccines or compositions and methods of producing recombinant reassortant BTV and ASHV vectors and methods of vaccination against BTV and ASHV.
Claims7
An immunogenic or vaccine composition comprising a recombinant Bluetongue Virus (BTV) vector comprising a vector backbone derived from a BTV-1 genome and a polynucleotide encoding a BTV-8 VP2 polypeptide and not a polynucleotide encoding a BTV-8 VP5 polypeptide.
A recombinant BTV vector comprising a vector backbone derived from a BTV-1 genome and a polynucleotide encoding a BTV-8 VP2 polypeptide and not a polynucleotide encoding a BTV-8 VP5 polypeptide.
A method of producing a recombinant BTV vector comprising transfecting a cell with RNAs encoding VP2 of BTV-8 and not a polynucleotide encoding a BTV-8 VP5 polypeptide;
- and RNAs encoding VP1, VP3, VP4, VP7, NS1, NS2, VP6NS4, and NS3/3A of BTV-1.
Dependencies are inferred from the claim text.